• ISO certificates
  • FAQ
  • Download center
InVivo Biotech Services
  • Products
    • in vivo Products
      • in vivo Antibodies
      • Isotype controls
    • Antibodies
      • Monoclonal
      • Recombinant
    • Proteins
    • SARS CoV-2 Antigens und Antibodies
  • Services
    • Antibody production
      • Monoclonal antibody production
      • Recombinant antibody production
    • Recombinant protein production
    • Cell line development
    • Additional services
      • Hybridoma development
      • Cell banking
      • Lyophilization
      • Protein Labeling
      • DNA Design
      • Larger scale DNA Preparation
      • Antibody sequencing & optimization
  • About us
    • Team
    • News
  • Careers
  • Contact us
0
Select Page
(de) Converting Rabbit hybridoma into recombinant

(de) Converting Rabbit hybridoma into recombinant

May 15, 2018 | Neuigkeiten

Mouse monoclonal antibodies are standard in research and diagnostic. Among all advantages of mouse monoclonal antibodies there is
(de) Meet InVivo at Medlab 2018 in Dubai

(de) Meet InVivo at Medlab 2018 in Dubai

May 15, 2018 | Neuigkeiten

MEDLAB will will take place from 5 – 8 February 2018 at the Dubai International Convention & Exhibition Centre, Dubai, UAE.
(de) Development of high producing cell lines

(de) Development of high producing cell lines

May 15, 2018 | Neuigkeiten

As part of an ILB and the state Brandenburginnovation project, InVivoworks on the develop ment of  a newre porter system and…

News-Archive

2024
  • Meet InVivo at MEDICA 2024 in Düsseldorf
  • Meet InVivo at EACR 2024 in Rotterdam
  • Meet InVivo at DBT 2024 in Berlin
  • Meet InVivo at CACLP 2024 in Chongqing
  • Meet InVivo at DKK 2024 in Berlin
2023
  • Meet InVivo at MEDICA 2023 in Düsseldorf
  • Meet InVivo at PEGS Europe 2023 in Lisbon
  • Meet InVivo at BioProcess International 2023 in Boston
  • Meet InVivo at AACC 2023 in Anaheim
  • Meet InVivo at PEGS Boston 2023
  • Meet InVivo at DBT 2023
2022
  • Meet InVivo at MEDICA 2022
  • Meet InVivo at Halle Conference on recombinant proteins
  • Meet InVivo at DBT in Hamburg and at PEGS in Boston
  • How to rescue a poorly performing hybridoma cell line
  • Information regarding Protein G purification processes
2021
  • InVivo at MEDICA 2021
  • InVivo at AACC 2021
  • AppNote: SARS-CoV-2 antigens successfully produced with comparable quality from transient transfection and stable cell pool expression systems
  • De novo sequencing of mABs with QTOF MS
  • Entwicklung von Corona-Antikörpern in Potsdam
  • InVivo digital business trip
2020
  • InVivo welcomes you at MEDICA 2020
  • InVivo at Festival of Biologics 2020
  • SARS-CoV-2 Antigens
  • Covid-19 Information
2019
  • InVivo at PEGS Europe
  • InVivo welcomes you at MEDICA 2019
  • Congratulations from the International Chamber of Commerce
  • Are you planning to visit AACC in August?
2018
  • (de) Converting Rabbit hybridoma into recombinant
  • (de) Meet InVivo at Medlab 2018 in Dubai
  • (de) Development of high producing cell lines

Recent News

  • Meet InVivo at MEDICA 2024 in Düsseldorf
  • Meet InVivo at EACR 2024 in Rotterdam
  • Meet InVivo at DBT 2024 in Berlin
  • Meet InVivo at CACLP 2024 in Chongqing
  • Meet InVivo at DKK 2024 in Berlin

Contact

phone: +49 (0) 3302 866 93-0
fax: +49 (0) 3302 866 93-62
email: info.invivo@bruker.com

InVivo BioTech Services GmbH 
Neuendorfstr. 24a
16761 Hennigsdorf
Phone: +49 (0) 3302 866 93-0
Fax: +49 (0) 3302 866 93-62
E-mail: info.invivo@bruker.com
  • Company
    • Products
    • Services
    • About us
    • Careers
    • Contact
  • Legal
    • Shipping costs
    • Terms and conditions
    • Imprint
    • Privacy notice
  • ISO certificates
  • FAQ
  • Download center
This website uses cookies for analytics and functionality purposes. We may share your information with our advertising and analytic partners. By clicking "Accept", you agree to our use of cookies and similar technologies.AcceptNoPrivacy policy
You can revoke your consent any time using the Revoke consent button.Revoke cookies